Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: A preliminary report in Korean patients

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 720-727

  Chang, Eugene ^a   Park, Dong Il ^a   Kim, Young Jin ^a   Kim, Bo Kyoung ^a   Park, Jung Ho ^a   Kim, Hong Joo ^a   Cho, Yong Kyun ^a   Sohn, Chong Il ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a   Kim, Hung Dai ^a   Kim, Dong Hoon ^a   Kim, Young Ho ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Colorectal cancer; Methylation specific PCR; Stool DNA

Indexed keywords

ALPHA4 INTEGRIN; DNA; PROTEIN P16; SECRETED FRIZZLED RELATED PROTEIN 2; TUMOR MARKER;

ADENOMA; ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; COLORECTAL TUMOR; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DNA METHYLATION; ENDOSCOPY; FECES CULTURE; FEMALE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SENSITIVITY AND SPECIFICITY; TUMOR VOLUME;

ADENOMA; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; COLORECTAL NEOPLASMS; DNA METHYLATION; FECES; FEMALE; HUMANS; KOREA; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 78149260396     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics 2005. CA Cancer J Clin 2005; 55:10-30.
2. Mandel JS, Bond JH, Church TR, et al: Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328:1365-71.
3. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O: Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348:1467-71.
4. Collins JF, Lieberman DA, Durbin TE, Weiss DG: Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med 2005; 142:81-5.
5. Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN: Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:132-41.
6. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61:759-67.
7. Fearon ER, Cho KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW, et al: Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 1990; 247:49-56.
8. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinzler KW, Vogelstein B: Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 1995; 55:5548-5550
9. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75:1027-1038
10. Baylin SB, Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nature 2006; 6:107-116
11. Jubb AM, Bell SM, Quirke P: Methylation and colorectal cancer. J Pathol 2001; 195:111-34.
12. Bestor TH: Gene silencing. Methylation meets acetylation. Nature 1998; 393:311-2.
13. Luo L, Chen WD, Pretlow TP: CpG island methylation in aberrant crypt foci and cancers from the same patients. Int J Cancer 2005; 115:747-51. (Pubitemid 40776698)
14. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, Thibodeau SN: Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58:3455-60.
15. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 2005; 11:1203-9.
16. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG: Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients, Cancer Res. 1999; 59:67-70.
17. Müller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, Mühlthaler M, Öfner D, Margreiter R, Widschwendter M: Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004. 363:1283-1285
18. Osborn NK, Ahlquist DA: Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005; 128:192-206.
19. Schroy PC, 3rd, Heeren TC: Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am J Prev Med 2005; 28:208-14.
20. Klaassen CH, Jeunink MA, Prinsen CF, et al: Quantification of human DNA in feces as a diagnostic test for the presence of colorectal cancer. Clin Chem 2003; 49:1185-7.
21. Loktionov A, O'Neill IK, Silvester KR, et al: Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 1998; 4:337-42.
22. Atkin W, Martin JP: Stool DNA-based colorectal cancer detection: finding the needle in the haystack. J Natl Cancer Inst 2001; 93:798-9.
23. Ahlquist DA, Skoletsky JE, Boynton KA, et al: Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119:1219-27.
24. Tagore KS, Lawson MJ, Yucaitis JA, et al: Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3:47-53.
25. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al: Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351:2704-14.
26. Wu GH, Wang YM, Yen AM, et al: Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC Cancer 2006; 6:136.
27. Huang ZH, Li LH, Yang F, et al: Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol 2007; 13:950-4.
28. Huang ZH, Li LH, Wang J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 2007; 52:2287-91.
29. Zitt M, Müller HM: DNA methylation in colorectal cancer-impact on screening and therapy monitoring modalities? Dis Markers 2007; 23:51-71.
30. Chan AO, Broaddus RR, Houlihan PS, et al: CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002; 160:1823-30.
31. Holzmann B, Gosslar U, Bittner M: alpha 4 integrins and tumor metastasis. Curr Top Microbiol Immunol 1998; 231:125-41.
32. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG: Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000; 275:2727-32.
33. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-87.
34. Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, Welshons WV, Wei SH, Davuluri RV, Plass C, Nephew KP, Huang TH: Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004; 64:8184-92.
35. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Dong Chen W, Pretlow TP, Yang B, Akiyama Y, Van Engeland M, Toyota M, Tokino T, Hinoda Y, Imai K, Herman JG, Baylin SB: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36:417-422
36. Losas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D: Promoter hypermethylation patterns of p16, O6-methylguanine-DNA- methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001; 61:939-942.
37. Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D: Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000; 60:892-895.
38. Nakayama H, Hibi K, Taguchi M, Takase T, Yamazaki T, Kasai Y, Ito K, Akiyama S, Nakao A: Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett. (2002), in press.
39. Sidransky D: Circulating DNA: what we know and what we need to learn. Ann. NY Acad. Sci. 2000; 906:1-4.
40. Jass JR, Young J, Leggett BA: Evolution of colorectal cancer: change of pace and change of direction. J Gastroenterol Hepatol 2002; 17:17-26. (Pubitemid 34304382)
41. Kinzler K, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996; 87:159-70.
42. Rex DK, Cutler CS, Lemmel GT, et al: Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112:24-8.
43. Nakagawa H, Nuovo GJ, Zervos EE, et al: Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001; 61:6991-5.